← All trials
NCT04741945
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2021
- Primary completion
- Nov 30, 2024
- Completion date
- Nov 30, 2025
- First posted
- Feb 5, 2021
- Last posted
- Feb 5, 2021
- Enrollment
- 24
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of CopenhagenLead sponsor
- Steno Diabetes Center CopenhagenCollaborator
- University of CopenhagenCollaborator
- University of CopenhagenCollaborator
- University of CopenhagenCollaborator
- University of CopenhagenSponsor investigator
- University of CopenhagenOverall official - principal investigator
- University of CopenhagenCollaborator
- Van Andel Research InstituteCollaborator
- Technical University of DenmarkCollaborator
- Region Hovedstadens ApotekCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.